Pacific Biosciences of California 過去の業績

過去基準チェック /06

Pacific Biosciences of Californiaの収益は年間平均-40.2%の割合で減少していますが、 Life Sciences業界の収益は年間増加しています。収益は年間13.9% 18.7%割合で増加しています。

主要情報

-40.2%

収益成長率

-30.8%

EPS成長率

Life Sciences 業界の成長	26.8%
収益成長率	18.7%
株主資本利益率	-87.0%
ネット・マージン	-227.7%
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Pacific Biosciences of California の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:P09 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	173	-394	165	146
30 Jun 24	189	-400	172	168
31 Mar 24	200	-297	174	182
31 Dec 23	201	-307	170	187
30 Sep 23	170	-309	169	185
30 Jun 23	146	-319	162	185
31 Mar 23	134	-321	161	189
31 Dec 22	128	-314	161	193
30 Sep 22	137	-299	153	193
30 Jun 22	140	-206	148	173
31 Mar 22	135	-175	138	145
31 Dec 21	131	-181	124	113
30 Sep 21	122	-37	105	88
30 Jun 21	106	-77	94	77
31 Mar 21	92	-59	80	69
31 Dec 20	79	29	73	64
30 Sep 20	80	-46	84	61
30 Jun 20	83	-51	71	59
31 Mar 20	90	-53	75	59
31 Dec 19	91	-84	75	60
30 Sep 19	82	-115	62	62
30 Jun 19	79	-111	68	61
31 Mar 19	76	-109	64	62
31 Dec 18	79	-103	63	63
30 Sep 18	84	-93	58	62
30 Jun 18	89	-90	58	63
31 Mar 18	88	-93	59	65
31 Dec 17	93	-92	59	65
30 Sep 17	94	-90	58	66
30 Jun 17	96	-86	56	68
31 Mar 17	97	-79	51	68
31 Dec 16	91	-74	48	68
30 Sep 16	101	-57	48	66
30 Jun 16	90	-37	46	65
31 Mar 16	94	-31	46	62
31 Dec 15	93	-32	45	60
30 Sep 15	73	-49	42	58
30 Jun 15	80	-60	41	54
31 Mar 15	67	-67	40	51
31 Dec 14	61	-66	38	48
30 Sep 14	53	-64	37	47
30 Jun 14	40	-76	38	46
31 Mar 14	34	-77	38	45
31 Dec 13	28	-79	39	45

質の高い収益: P09は現在利益が出ていません。

利益率の向上: P09は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: P09は利益が出ておらず、過去 5 年間で損失は年間40.2%の割合で増加しています。

成長の加速: P09の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: P09は利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( -0.7% ) と比較することは困難です。

株主資本利益率

高いROE: P09は現在利益が出ていないため、自己資本利益率 ( -87.01% ) はマイナスです。

Pacific Biosciences of California 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors

過去基準チェック /06